Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Περιεχόμενα  Φάρμακα Α - Ζ  Συγχορήγηση

ALMOGRAN Film-coated tablet (2015)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Almogran/Amignul/Almotrex 12.5 mg Film-coated tablet.

Qualitative and quantitative composition

Each tablet contains almotriptan 12.5 mg as almotriptan D,L-hydrogen malate. For the full list of excipients, see section 6.1.

Pharmaceutical form

Film-coated tablet. White, circular, biconvex film-coated tablet with an A engraved on one side.

Therapeutic indications

Acute treatment of the headache phase of migraine attacks with or without aura.

Posology and method of administration

Almogran/Amignul/Almotrex should be taken with liquids as early as possible after the onset of migraine-associated headache but it is also effective when taken at a later stage. Almotriptan should not ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. As with other 5-HT<sub>1B/1D</sub> receptor agonists, almotriptan should not be used in patients with a history, ...

Special warnings and precautions for use

Almotriptan should only be used where there is a clear diagnosis of migraine. It should not be used to treat basilar, hemiplegic or ophthalmoplegic migraine. As with other acute migraine therapies, before ...

Interaction with other medicinal products and other forms of interaction

Interaction studies were performed with monoamine oxidase A inhibitors, beta-blockers, selective serotonin re-uptake inhibitors, calcium channel blockers or inhibitors of Cytochrome P450 isoenzymes 3A4 ...

Pregnancy and lactation

Pregnancy For almotriptan, very limited data on pregnant patients are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, ...

Effects on ability to drive and use machines

There are no studies on the effect of almotriptan on the ability to drive or operate machinery. However, since somnolence may occur during a migraine attack and has been reported as a side effect of treatment ...

Undesirable effects

Almogran/Amignul was evaluated in over 2700 patients for up to one year in clinical trials. The most common adverse reactions at the therapeutic dose were dizziness, somnolence, nausea, vomiting and fatigue. ...

Overdose

The most frequently reported adverse event in patients receiving 150 mg (the highest dose administered to patients) was somnolence. Overdose should be treated symptomatically and vital functions should ...

Pharmacodynamic properties

Pharmacotherapeutic group: Antimigraine. Selective 5-HT1 receptor agonist ATC code: N02CC05 Mechanism of action Almotriptan is a selective 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptor agonist. These ...

Pharmacokinetic properties

Almotriptan is well absorbed, with an oral bioavailability of about 70%. Maximum plasma concentrations (C<sub>max</sub>) occur approximately between 1.5 and 3.0 hours after administration. The rate and ...

Preclinical safety data

In safety pharmacology, repeated dose toxicity and reproduction toxicity studies, adverse effects were observed only at exposures well above the maximum human exposure. Almotriptan did not show any mutagenic ...

List of excipients

Tablet core: Mannitol (E-421) Microcrystalline cellulose Povidone Sodium starch glycolate Sodium stearyl fumarate Coating material: Hypromellose Titanium dioxide (E-171) Macrogol 400 Carnauba wax

Incompatibilities

Not applicable.

Shelf life

Shelf life: 5 years.

Special precautions for storage

This medicinal product does not require any special storage conditions.

Nature and contents of container

Boxes containing aluminium foil blisters with 2, 3, 4, 6, 7, 9, 12, 14 or 18 tablets. Not all pack sizes may be marketed.

Special precautions for disposal and other handling

No special requirements.

Marketing authorization holder

Almirall, S.A., Ronda General Mitre, 151, 08022, Barcelona, Spain

Marketing authorization number(s)

PL 16973/0005

Date of first authorization / renewal of the authorization

Date of last renewal: December 2009

Date of revision of the text

July 2015

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: